NCT00803361

Duloxetine for the Treatment of Generalized Anxiety Disorder

Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Duloxetine	60 to 120 mg, capsules, oral, once a day for 15 weeks
DRUG	Placebo	placebo capsules, oral, once a day for 15 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2008-12-05
• Last updated: 2010-12-17
• Results posted: 2010-12-17

Locations

7 sites across 1 country: China